Background Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based
adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection …

3737 Background: The improved safety profile of the oral fluoropyrimidine X (Xeloda) versus
bolus 5-FU/LV has been demonstrated in over 3000 pts in 3 large randomized trials in 1st …

Objectives: The benefit of adding oxaliplatin to adjuvant fluoropyrimidine chemotherapy in
patients> 70 years is controversial. This retrospective audit investigated usage, benefit and …

Age is a major risk factor for colorectal cancer (CRC), with a median age of approximately 70
years at diagnosis. Approximately 50% of cases develop in patients older than 65 years, and …

Objective Randomized trials have established the effectiveness of 5-fluorouracil-based
adjuvant chemotherapy for stage III resectable colon cancer but the toxicity has not been …

Background Elderly patients with primary colorectal cancer (CRC) are less frequently treated
with adjuvant chemotherapy than younger patients due to concerns regarding toxicity and …

9030 Background: Elderly/frail patients, though commonly treated, are under-represented in
clinical trials. Evidence is needed to guide choices of drugs and doses in this population …

A comment on this article appears in" Reply to H. Wong et al." J Clin Oncol. 2013 Feb 1; 31
(4): 512-3. This is a comment on" Effect of adjuvant chemotherapy on survival of patients …

Background Some studies suggest that older patients have reduced or no benefit from the
addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III colon …

Abstract Background Only 50–70% of elderly colon cancer patients could complete the
recommended 6 months of postoperative chemotherapy. It is unknown whether a shorter …